Company news
Kalvista Pharmaceuticals, Inc. (NASDAQ:KALV) news
Kalvista Pharmaceuticals, Inc. news releases on 6ix. Latest, May 27, 2021: KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Press releases — page 4
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
May 26, 2021
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer
May 2, 2021
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
April 19, 2021
KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors
March 18, 2021
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 15, 2021
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
February 9, 2021
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 8, 2021
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise
October 14, 2020
KalVista Pharmaceuticals Provides Operational and Financial Update
April 6, 2020
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
March 9, 2020
KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs
February 9, 2020
KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema
December 8, 2019
KalVista Pharmaceuticals Reports Fiscal Second Quarter Results
December 2, 2019